Phase 4
Completed N=70
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Transplant Complication · CMV
Source: ClinicalTrials.gov NCT06034925 ↗
Enrolled (actual)
70
Serious AEs
4.3%
Results posted
Apr 2026
Primary outcomePrimary: Clinical Significant Leukopenia — 8; 1 Participants
◆ Published Evidence
Not yet cited
0citations
A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol.
Summary
The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).
Linked Publications
-
A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Significant Leukopenia |
8; 1 | — |
| PRIMARY CMV Infection |
8; 11 | — |
Eligibility Criteria
Inclusion Criteria
- Kidney transplant recipient at study institution
- =7 days of transplant
- Received at least one dose of rATG induction or patient is D+/R- CMV serostatus
Exclusion Criteria
- Age <18 years at time of transplant
- Recipient of pancreas, liver, heart, lung transplant
- Recipient of investigational, non-FDA approved medication
Data sourced from ClinicalTrials.gov (NCT06034925) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.